BUZZ-Biohaven slides on wider-than-expected quarterly loss

Drug developer Biohaven's BHVN.N shares fall 4.1% to $35.66

Co posts Q4 adj. loss of $1.71 per share compared with analysts' average estimate of a loss of $1.57, according to data compiled by LSEG

Separately, co says its experimental drug, BHV-1300, reduced Immunoglobulin G, a type of antibody, by 84% in an early-stage study to treat an autoimmune condition called Graves' disease

Co plans to initiate a mid-stage study in patients with the disease in mid-2025

BHVN has fallen 21.4% in the last 12 months